FilingReader Intelligence
Tiantan Biological abandons Pailin Biotech acquisition citing integration risks
August 4, 2025 at 09:32 AM UTC•By FilingReader AI
Beijing Tiantan Biological Products Corp. will abandon its acquisition of 21.03% of Pailin Biotech, citing high transaction timelines and potential integration risks.
The decision defers the acquisition to its controlling shareholder, China National Biotec Group, which will address the resulting horizontal competition issues.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Notice of Beijing Tiantan Biological Products Co., Ltd. regarding the convening of the first extraordinary general meeting of shareholders in 2025August 4, 2025 at 08:00 AM UTC
Announcement of resolutions from the twenty-third meeting of the ninth board of directors of Tiantan biological.August 4, 2025 at 08:00 AM UTC
SSE:600161•Shanghai Stock Exchange
Pharmaceuticals
News Alerts
Get instant email alerts when Beijing Tiantan Biological Products Corp publishes news
Free account required • Unsubscribe anytime